How AIQ Treatment Response Assessments improve patient management

Identify and treat intrinsic resistance shortly after
the initiation of therapy

Early resistance to treatment in less than 10% of lesions correlates to significantly shorter time to progression.
The TRA provides quantitative and spatial information about early treatment resistance.
Based on the degree of intrinsic resistance, the clinical care team can consider localized treatment of resistant lesions, the addition of another therapeutic, or change to a different therapy approach.

Identify and treat
acquired resistance

Patients receiving non-curative oncology treatment will often develop acquired treatment resistance. In many cases, this resistance begins in a small number of lesions that clone and spread over time.
By repeating AIQ Solutions Treatment Response Assessments over the course of treatment, the clinical care team can identify and quantify acquired resistance.
Based on the degree of acquired resistance, the clinical care team can consider localized ablation of resistant lesions or change to a different therapeutic approach.

How AIQ Treatment Response Assessments help reduce costs

An AIQ Solutions patient management case study


AIQ conducted a retrospective study of a patient diagnosed with prostate cancer metastatic to bone. The patient was treated with a nonsteroidal antiandrogen medication for 54 weeks. At that point, the patient's PSA began to climb, and the patient reported new pain in his pelvis; as a result, the therapy was changed to Docetaxel. Despite this change, the patient’s disease continued to progress. The patient's treatment response was assessed using AIQ technology at 12, 54, and 62 weeks into treatment.


At 12 weeks, there was a substantial decrease in tumor burden, with the majority of lesions improving on therapy.  Repeated evaluation at week 54 showed progressive disease in the left pelvis with the remainder of disease stable or improved. A subsequent review conducted eight weeks after switching the patient's therapy to chemotherapy medication (62 weeks total) showed not only ongoing progression in the left pelvis but also disease progression among many of the lesions which were still responding to the nonsteroidal antiandrogen medication at 54 weeks.


Had AIQ's medical device technology platform been available, a decision to change the patient's care pathway and administer localized radiation to the left pelvis could have been made, allowing the patient to maintain disease control on his nonsteroidal antiandrogen therapy. Because most lesions were still responding well to that therapy, this approach may have prevented the negative outcomes subsequently observed.

SUVtotal Response

T1 (12 week response)
T2 (54 week response) 
Progression Scan
T3 (62 week response)

PSA Response

How we support the clinical care team

Treating Physicians

Every day, you are challenged with trying to understand how disease evolves within your patient, while at the same time under pressure to reduce treatment costs. Our technology platform supplies intelligence, analytics, and insights you cannot get from other medical devices.  We help you make a real difference for your patients every day.  Our technology provides information to help fight the tough battles and develop effective strategies for treatment management.

Radiologists and Nuclear Medicine

By using algorithmic analysis for detecting the volume of lesions, determining their boundaries, quantifying disease burden, and assessing temporal change, AIQ's technology provides accurate evaluations of treatment response.  You get both graphical and quantitative data faster, allowing you to focus on interpreting the patient's condition and recommending changes to the care plan. What we offer does not replace your medical expertise; it amplifies it.  AIQ broadens the information landscape available to treat patients, using information that is reliable, proven, and actionable.

AIQ works within

What questions do you have?

Learn more about how AIQ Solutions can optimize your patient's care.

AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use,
see: https://www.accessdata.fda.gov/scripts/cdrh/cfcodes/cfPMN/pmn.cfm?ID=K173444